Zydus Lifesciences gains on entering to SSSA to subscribe equity shares of Torrent Urja 26, Torrent Urja 25
Zydus Lifesciences is currently trading at Rs 926.95, up by 1.85 points or 0.20% from its previous closing of Rs 925.10 on the BSE.
The scrip opened at Rs 935.00 and has touched a high and low of Rs 935.00 and Rs 924.05 respectively. So far 15568 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 1 has touched a 52-week high of Rs 1323.90 on 09-Aug-2024 and a 52-week low of Rs 797.05 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs 935.00 and Rs 896.25 respectively. The current market cap of the company is Rs 93152.11 crore.
The promoters holding in the company stood at 74.99%, while Institutions and Non-Institutions held 18.33% and 6.68% respectively.
Zydus Lifesciences has entered into Share Subscription and Shareholders’ Agreement (SSSA) on May 28, 2025, to subscribe to equity shares of Torrent Urja 26. In line with the commitment to enhance the share of renewable power source in its operations and to comply with regulatory requirement for being a ‘captive user’ under Electricity Act, 2003, the Company has entered into SSSA to acquire up to 26.20% equity shares of Torrent Urja 26, for setting up captive hybrid power project in Gujarat.
Further, Zydus Lifesciences and its various subsidiaries have also entered into SSSAs on May 28, 2025, to subscribe to equity shares of Torrent Urja 25. In line with the commitment to enhance the share of renewable power source in its operations and to comply with regulatory requirement for being a ‘captive user’ under Electricity Act, 2003, the Company and its various subsidiaries have entered into SSSAs to acquire up to 22.06% equity shares of Torrent Urja 25, for setting up captive hybrid power project in Gujarat.
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
